
Surmodics (SRDX) Stock Forecast & Price Target
Surmodics (SRDX) Analyst Ratings
Bulls say
Surmodics Inc. reported a revenue increase of 17% in F4Q24, excluding SurVeil license fees, marking a significant improvement compared to the previous quarter's 9% growth. The company's revenue estimates for FY25 and FY26 have been raised, projecting revenues of $137.6 million and $148.8 million respectively, which indicates strong growth expectations. Additionally, the successful distribution of the SurVeil drug-coated balloon by Abbott is anticipated to contribute substantially to revenue, suggesting a promising outlook for the company’s financial performance.
Bears say
Surmodics Inc's first-quarter revenue for fiscal 2025 fell short of consensus estimates, marked by a significant slowdown in revenue growth, which contracted by 2% compared to a growth of 17% in the previous quarter, primarily due to a decline in SurVeil sales. The company's revenue in this quarter was reported at $29.9 million, reflecting a 3% decrease when excluding SurVeil license fee revenue, with revised fiscal year 2025 and 2026 revenue estimates lowered to account for anticipated continued declines in SurVeil product sales. Furthermore, expectations indicate a $5 million revenue decline for SurVeil DCB products in fiscal 2025, as replenishment orders are failing to compensate for prior stocking orders in fiscal 2024.
This aggregate rating is based on analysts' research of Surmodics and is not a guaranteed prediction by Public.com or investment advice.
Surmodics (SRDX) Analyst Forecast & Price Prediction
Start investing in Surmodics (SRDX)
Order type
Buy in
Order amount
Est. shares
0 shares